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 Salvage Radical Prostatectomy after 
External Beam Radiation Therapy: 
A Systematic Review of Current 
Approaches 
vage therapy after EBRT may provide long-term local control 
in appropriately selected patients, although toxicity is often 
significant.  Conclusions: Our results suggest that for local-
ized prostate cancer recurrence after EBRT, the selection of a 
local treatment modality should be made on a patient-by-
patient basis. An improvement in selection criteria and an 
integrated definition of biochemical failure for all salvage 
methods are required to determine which provides the best 
oncological outcome and least comorbidity. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Biochemical recurrence (BCR) rates after primary ex-
ternal beam radiation therapy (EBRT) for prostate cancer 
have been reported to reach 63%. In 20–30% of the cases, 
these are local recurrences, which means patients could 
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 Abstract 
 Background: Radical external beam radiotherapy (EBRT) is a 
standard treatment for prostate cancer patients. Despite 
this, the rate of intraprostatic relapses after primary EBRT is 
still not negligible. There is no consensus on the most appro-
priate management of these patients after EBRT failure. For 
these patients, local salvage therapy such as radical prosta-
tectomy, cryotherapy, and brachytherapy may be indicated. 
Objective: The objectives of this review were to analyze the 
eligibility criteria for careful selection of appropriate patients 
and to evaluate the oncological results and complications 
for each method.  Methods: A review of the literature was 
performed to identify studies of local salvage therapy for pa-
tients who had failed primary EBRT for localized prostate 
cancer.  Results: Most studies demonstrated that local sal-
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still benefit from local salvage therapy  [1, 2] . Neverthe-
less, only a small portion of these cases (0.9–2%) are actu-
ally managed with salvage radical prostatectomy (SRP), 
whereas most end up receiving castration therapy, re-
gardless of the relapse being local or metastatic  [1, 3] . 
 Careful patient selection is important to guide the de-
cision-making process in the management of patients 
with local recurrence after EBRT failure. SRP, defined as 
a radical prostatectomy procedure performed for local 
failure after primary EBRT, has been refined over the past 
decade. Increasing surgical experience has resulted in a 
decrease in the rate of surgical complications. In addition, 
biochemical outcomes reported in recent series suggest a 
superiority of SRP over other salvage treatment modali-
ties, such as cryotherapy, high-intensity focused ultra-
sound, or brachytherapy  [4] . 
 The aim of the present study is to provide a systematic 
evidence-based analysis of the current literature on SRP 
in patients with radiation-recurrent prostate cancer. 
 Literature Search and Study Selection 
 A systematic review of the literature was performed in 
July 2014 using the PubMed database (http://www.ncbi.
nlm.nih.gov/pubmed/). Identification and selection of 
the studies was conducted according to Preferred Report-
ing Items for Systematic Reviews and Meta-analysis cri-
teria (www.prisma-statement.org) using the search term: 
‘salvage radical prostatectomy’ .  Only studies specifically 
looking at the outcomes of SRP after failure of EBRT were 
considered for the present analysis. The level of evidence 
was reported as described by the Oxford Center for Evi-
dence-Based Medicine (www.cebm.net). Data related to 
the following topics were specifically analyzed: definition 
of BCR after EBRT and identification of local recurrence. 
 Definition of Recurrence after EBRT 
 All of the reported series on SRP consider as a defini-
tion criterion for BCR three or more consecutive increas-
es of prostate-specific antigen (PSA) after nadir, occur-
ring at least 6 months after the nadir (previous ASTRO 
definition). More recent series have adopted the Phoenix 
‘nadir + 2’ definition (most recent ASTRO definition)  [5] . 
This last criterion was conceived with the aim of ruling 
out patients with fluctuating PSA (approx. 25% of all 
EBRT-treated patients), thus preventing overtreatment 
 [6] . However, two factors may potentially delay relapse 
diagnosis when adopting this ‘updated’ definition: the 
lack of an ideal (or, at least, desired) PSA nadir value, and 
the need to obtain a ‘nadir + 2 ng/ml’ level to consider the 
PSA elevation as BCR. 
 According to Zelefski et al.  [7] , the ideal nadir should 
be <0.5 ng/ml, as patients developing metastatic progres-
sion were found to have higher nadir values (mean of 2.2) 
than those with local relapse only (mean of 1.1). The nadir 
value after EBRT strongly correlates with different time 
points; thus, it should not be considered a value by itself 
but only a ‘time-dependent variable’. According to this 
group of investigators, ‘evaluation should be performed 
to rule out persistent local and systemic disease for pa-
tients with PSA nadir levels >1.5 ng/ml at 2 years’, i.e. even 
without having reached the nadir +2 level.
 In contrast, an increase in PSA of +2 greater than the 
nadir may potentially delay the diagnosis of disease fail-
ure, resulting in detrimental outcomes mostly in patients 
with local recurrence or persistence, as these patients can 
meanwhile develop metastatic progression. According to 
Stephenson et al.  [8] , this EBRT failure definition can de-
lay the diagnosis by up to 5 years, thus minimizing the 
likelihood of a local salvage approach.
 Hence, BCR after primary EBRT requires a more pre-
cise definition to improve the balance between the poten-
tial effects of delaying the detection of failure and the risk 
of overtreatment. Additional criteria, such as the timing 
 [7, 9] and pattern  [10] of the PSA decrease after RT, may 
be more useful for characterizing and understanding the 
failure phenomenon.
 The scenario is more complicated in the case of high-
risk patients who have received EBRT with androgen 
 deprivation therapy (ADT)  [11] . These patients will more 
easily obtain very low nadir levels (close to 0 presumably 
due to ADT), but they might have higher metastatic risk. 
Three scenarios should be expected for these cases: (1)  At 
9–12 months after EBRT, ADT is stopped, and a low PSA 
kinetic BCR occurs; these patients have a higher probabil-
ity of only local recurrence/persistence of the disease  [12] . 
Thus, waiting until the PSA elevation reaches 2 ng/ml 
could be truly detrimental for any local salvage therapy. 
(2)  After ADT suspension, a high PSA kinetic BCR  occurs, 
indicating metastatic disease progression of a subclinical, 
yet micrometastatic, disease at presentation. (3)  PSA el-
evation occurs during ADT, indicating a shift toward an-
drogen independence, which is associated with a poor 
prognosis  [13] . 
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 Identification of Local Recurrence 
 Once a BCR is recorded, criteria are necessary to iden-
tify potential candidates for local salvage therapy, where 
a local (vs. systemic) recurrence is most likely. 
 PSA kinetics can be useful for recognizing local recur-
rence or persistence of disease. A short PSA doubling 
time (<3 months) indicates a rapidly growing tumor, with 
a higher risk of clinical progression to metastatic disease 
 [11] . A longer PSA doubling time (>6–10 months) is as-
sociated with a higher likelihood of local failure  [14] . 
 Local failure should be ideally proven by means of a 
biopsy, despite the reported false-positive (up to 60%) 
and false-negative (up to 20%) rates  [15] . In the series by 
Vance et al. [16] the 2-year post-RT prostate biopsy was 
atypical or positive in 26% of cases, and it was statisti-
cally correlated with PSA level, demonstrating that post-
RT prostate biopsy can be useful in identifying patients 
who are suitable for aggressive salvage therapy.
 In contrast, Kaplan et al. [17] showed in their series of 
patients who underwent radical cystoprostatectomy at a 
median time of 60 months from EBRT that histological 
evidence of prostate cancer was present in 50% of patients 
with no BCR at the time of surgery. Although the bio-
logical significance of the presence of active prostate can-
cer cells in this selected population is uncertain, the study 
highlights the limitations of PSA in monitoring prostate 
cancer disease activity following definitive RT.
 In other series, Gleason score-indefinable rates were 
present in 18–25% of cases  [18, 19] ; current pathology 
guidelines discourage the use of Gleason scoring in spec-
imens obtained from previously treated patients (ADT, as 
well as RT), as the induced histological changes could 
 determine an apparently more clustered gland pattern. 
Markers of cell proliferation (such as Ki-67) could pro-
vide a more objective and reliable pathologic evaluation 
of post-RT prostate biopsies  [15, 20] .
 Imaging workups are ordered to exclude metastatic 
progression and often also to guide biopsy. New encour-
aging data have been obtained with dynamic contrast-
enhanced MRI  [21] and diffusion MRI imaging  [22–24] . 
Moreover, for patients with PSA levels >2.5 ng/ml,  11 C-
choline PET has been reported to have a sensitivity of 89% 
and a positive predictive value of 72%  [25, 26] . Similarly, 
the sensitivity and specificity of  18 F-choline PET in de-
tecting bone metastases from prostate cancer were re-
ported to be 79 and 97%, respectively  [27, 28] . Neverthe-
less, no consensus exists yet regarding the panel of imag-
ing modalities to be performed to distinguish local from 
systemic recurrence. 
 Salvage Radical Prostatectomy 
 Outcomes 
 Twenty-seven single-center or multicenter retrospec-
tive case series (level of evidence: 4) were reported on the 
use of SRP for radiorecurrent prostate cancer ( table 1 ). In 
two series, the outcomes of SRP have been compared to 
those of other forms of salvage therapy (cryotherapy and 
brachytherapy). 
 The careful evaluation of SRP prognostic factors is of 
paramount importance for the appropriate selection of 
patients. Many retrospective studies and two high-quality 
literature reviews  [29, 30] have highlighted the main 
prognostic factors, which have emerged from retrospec-
tive univariate or multivariate analyses. As Chade et al. 
 [30] have shown, the strongest prognostic factor was pre-
SRP PSA, which was shown to often predict progression-
free, cancer-specific or overall survival; evaluation of pre-
SRP PSA should be followed by prostate biopsy Gleason 
scoring (although the data should be considered very 
carefully because of the objective difficulties in correctly 
and reproducibly scoring post-RT prostate needle speci-
mens, as previously shown). Further prognostic factors, 
such as pre-RT clinical stage, percentage of positive cores 
at biopsy and PSA doubling time >12 months, have been 
reported to predict SRP clinical outcomes in fewer series.
 Type of Surgery 
 The surgical salvage approach is not limited to SRP; 
pelvic exenteration  [31] , cystoprostatectomy  [32–38] , or 
prostatectomy with permanent cystostomy  [39] can also 
be considered. The frequency of these demolition proce-
dures was clearly decreased in the last published surgical 
salvage series because of the migration of the patients in 
the initial early stages as a result of an early diagnosis of 
disease relapse.
 The median follow-up ranged from 12.5 to 120 months. 
The definition of BCR after SRP varies depending on the 
institution, but may be PSA >0.12  [39] , >0.2  [6, 37, 40–
46] , or >0.4 ng/ml  [32, 47, 48] . The reported BCR-free 
survival probability ranges between 28 and 93%. Because 
the BCR-free survival definition depends on the PSA na-
dir, it is also a time-dependent variable, and by plotting 
the reported BCR-free rates with the follow-up lengths of 
different series, a decreasing tendency can be observed 
(Spearman’s rank correlation, 2-sided p = 0.05), which is 
clearly more significant (R 2 = 58.5 vs. 15.7%, respectively) 
if only series with >40 patients are considered ( fig. 1 )  [8, 
19, 37, 41–43, 45] . 
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 BCR-free rates are also correlated with the organ-con-
fined disease (OCD) rates of the series (R 2 = 14.2%); the 
significance of the correlation improves (R 2 = 85.8%) if 
series with only >40 patients are considered (excluding 
the series by Chade et al.  [19] , which was too heteroge-
neous and multicentric and extended over a rather long 
[25 years] period) ( fig. 2 )  [8, 37, 41, 43, 45, 47, 49] . The 
series published before 1995 had fewer patients than 
those published after 1998 (mean 27.8 vs. 62.7, not con-
sidering the series by Chade et al.  [19] for the previously 
mentioned reasons; t test: p = 0.047), and the rate of OCD 
was clearly higher, thus confirming the migration of pa-
tients toward lower stages (30.75 vs. 47%; t test p = 0.02). 
 The positive surgical margin rate decreased from an 
average of 47.5% before 1995 to an average of 20.8% after 
1995 (Student’s t test: p = 0.002). Even if a longer follow-
up is associated with worse biochemical control, early di-
agnosis of recurrence (by determining higher OCD with 
lower positive surgical margin rates) will allow for higher 
BCR-free rates. In fact, the reported cancer-specific sur-
vival (CSS) has ranged from 70 to 83% at 10 years ( ta-
ble 1 ).
 The Role of Lymph Node Dissection 
 Lymph node dissection (LND) associated with SRP was 
reported in only few series ( table 1 ), and it was not stan-
dardized, which precludes both the assessment of its pos-
sible impact on CSS and any comparison among series. 
 In a completely different setting, Winter et al.  [50] 
were the first to demonstrate, in a small series of 6 pa-
tients, the role of  11 C-choline PET/CT-guided secondary 
lymph node surgery in patients with PSA failure and sin-
gle lymph node recurrence after radical retropubic pros-
tatectomy, showing a complete permanent PSA remis-
sion without adjuvant therapy in 3 patients (median fol-
low-up: 24 months, range: 21–35).
 Table 1.  Oncological outcomes and complication rates of SRP series reported in the literature
Reference
(first author)
Year Patients,
n
Follow-up,
months
OCD,
%
BCR,
%
CSS,
%
PSM,
%
Involved 
LN, %
BL,
l
Rectal 
injury, %
Anasto-
motic 
stenosis, %
Incon-
tinence,
%
Neerhut [58] 1988 16 20 25 88 0.9 19 25 25
Link [57] 1991 14 18 30.8 57 43 1 0 9 55
Zincke [59] 1992 32 44 82 1.219 6 19 27
Ahlering [60] 1992 11 53.5 71 71 0 0 64
Stein [35] 1992 13 38.5 1.1 7.7 15 64
Pontes [36] 1993 35 12 – 120 30 28 79 70 12 9 11 46
Brenner [61] 1995 10 30 30 30 40
Rogers [47] 1995 40 39.3 22 47 95 37 5 0.91 15 28 58
Lerner [37] 1995 79 50 39 53 72 6 12 39
Gheiler [32] 1998 30 36.1 39.5 47 87 13 16 1.1 3.3 16.7 50
Garzotto [62] 1998 29 63.6 28 69 31 1.16 6.9 22 67
Cheng [55] 1998 86 70 64 16
Amling [40] 1999 108 39 43 70 36 18 6 21 51
Stephenson [8] 2004 100 60 50 66 10 7 1 1 30 32
Bianco [41] 2005 100 60 35 55 73 21 9
Ward [38] 2005 138 84 39 77 10 22 44
Heidenreich [42] 2006 25 12.5 93 100 8 8
Darras [63] 2006 11 83 81 55 91 0 0
Sanderson [48] 2006 51 25 47 36 28 30
Boris [64]1 2009 11 20 73 27 18 0.113 9 9 20
Seabra [43] 2009 42 18 74 79 100 0 0.3 4.8 50 72
Leonardo [44] 2009 32 35 53 75 34 0 0.55 0 12 79
Paparel [45] 2009 146 45 44 54 16 13
Eandi [46]1 2010 18 18 50 67 28 5.5 0.15 17 17 67
Heidenreich [49] 2010 55 23 73 87 11 20 0.36 2 11 19
Chade [19] 2011 404 55 55 37 83 25 16
Zugor [53]1 2014 13 46 0   0.13 0 0 46
PSM = Positive surgical margin. 1 Only robotic series.
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 After 1 year, Rigatti et al.  [51] showed that 24 out of
28 patients (85.7%) who received no adjuvant ADT after 
salvage LND had verified BCR after a mean follow-up of 
38.9 months (median: 14.9), corresponding to a 5-year 
BCR-free survival rate of 19% (in only the ‘responder’ 
subgroup). 
 Consequently, performing LND during SRP in LN-
choline-PET-negative patients might have only a small 
impact on disease control.
 Surgical Complications 
 Intraoperative complications and functional results 
have been quite stable over time, showing a slight (but not 
statistically relevant) improvement. The only relevant as-
sociation was found by plotting the rectal injury rate and 
the blood loss (BL) against the OCD rate in different pub-
lished series, and the results showed, as expected, that lo-
cally advanced disease exposes the patient to higher intra-
operative risk, at least with regard to rectal injury (R 2 = 
19%) and BL (R 2 = 54%).
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 Fig. 1. BCR-free survival rates plotted with the mean follow-up ( a ) and only in series with >40 patients ( b ). 
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 The lower reported rates of BL in the last series were 
caused by the presence in the review of two series of ro-
botic SRP  [46, 52, 53] . The average rates of reported rectal 
injury, anastomotic stricture, and incontinence were 6.8, 
18.3, and 47.8%, respectively.
 The introduction of minimally invasive approaches 
(laparoscopy and robotic laparoscopy), themselves hav-
ing evolved from SRP, has resulted in some advantages 
( table 2 ), at least with regard to the rates of overall and 
serious complications (Clavien >2). 
 Thus, although difficult and challenging, SRP has been 
shown to present no relevant technical difficulties in 
high-volume centers. Moreover, it is also a ‘land of con-
quest’ for minimally invasive approaches, e.g. robotic 
SRP  [53, 54] . 
 Early diagnosis and appropriate selection of patients 
will improve oncologic results and decrease the intraop-
erative complication rate (BL and rectal injuries, which 
clearly depend on the disease stage). Concerning sexual 
 Table 2.  Minimally invasive SRP series: oncologic outcomes and 
complication rates
Reference
(first author)
Technique Year Cases,
n
Clavien >2
complication 
rate, %
Inconti-
nence
rate, %
Vallancien [52] laparoscopic 2003 84 0 29
Stolzenburg [65] laparoscopic 2007 9 11 22
Nunez-Mora [66] laparoscopic 2009 9 11 33
Kaouk [67] robotic 2008 7 0 25
Boris [64] robotic 2009 11 9 20
Eandi [46] robotic 2010 18 17 67
Strope [68] robotic 2010 6 33 100
Chauhan [69]
Zugor [53]
robotic
robotic
2011
2014
15
13
6
15
29
54
 Table 3.  ED and SRP: literature overview
Reference
(first author)
Cases, n Pre-SRP ED,
%
Post-SRP ED,
%
Link [57] 75 57 100
Stephenson [8] 1,288 – 72
Masterson [70] 372 53 79
Leonardo [44] 120 91 91
Darras [63] 72 – 100
Gotto [71] 54 67 92
Heidenreich [49] 403 73 93
Vallancien [52] 84 72 100
Stolzenburg [65] 9 67 100
Nunez-Mora [66] 9 80 100
Boris [64] 11 10 80
Eandi [46] 18 56 100
Strope [68] 6 50 100
Chauhan [69]
Zugor [53]
15
13
33
38
100
77
 Table 4.  Clinical outcome of main salvage cryotherapy and high-
intensity focused ultrasound (a) and recently published SBT series 
(b) 
a    Salvage cryo and high-intensity focused ultrasound series 
Reference
(first author)
Follow-
up,
months
n BCR-
FS,
%
Rectal
fistula,
%
Inconti-
nence
Po-
tency
Pisters [56] 17 150 42 1 44
Pisters [72] 21.6 279 58.9 1.2 89.8
Pisters [73] 66  56 21
Perrotte [74] 16.7 150 28 15.2
Spiess [75] 41 797 34
Williams [76] 90 187 39
Chin [77] 43 106 97 3.3  8.5
Miller [78] 16.8  33 33 0  4
De la Taille [79] 21.9  43 60
Han [80] 20  18 72 0  7
Donnelly [81] 20  46 72 2.2  6.5 55.6
Ismail [82] 33.5 100 59 1 13 42.9
Bahn [83] 82.3  59 59 3.4  4.3
Eisenberg [84] 18  15 50  6.7
Ng [85]
Philippou [98]
39
24 
187
 19 
56
58 
37
Murat [86]1 36 167 55.7 3 49.5
Uchida [87]1
Mallick [96]
Gelet [97]
24 
12
40
 22
 50
106
52 
54
40
4.5 18.2
b Recently published SBT series
Reference
(first author)
Year n Follow-up,
months
BCR-FS,
%
Grade 3 – 4 
toxicity, %
Beyer [88] 1999 17 62 53
Grado [89] 1999 49 64 34 16
Wong [90] 2006 17 44 75 47
Allen [91] 2007 12 45 63 0
Nguyen [92] 2007 25 47 70 30
Lee [93] 2008 21 36 38 0
Aaronson [94] 2009 24 30 88 4
Burri [95]
Shimbo [99]
2010
2012
37
15
86
33
54
66
11
  7
BCR-FS = BCR-free survival. 1 High-intensity focused ultra-
sound series.
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function, erectile dysfunction (ED) is often present before 
SRP ( table 3 ), and even in patients with residual sexual 
function after RT, it should not be a problem in this set-
ting (i.e. post-RT failure). However, the most common 
salvage approach proposed in these cases is ADT, which 
is well known to induce ED. The CAPSURE data, which 
were recently analyzed and published by Agarwal et al. 
[1] , showed that 93.5% of patients presenting with post-
RT failure (including a relevant number with only local 
relapse) received and accepted castration therapy, despite 
the adverse effect of ED.
 Comparison with Other Local Salvage Modalities 
 Incontinence rates after SRP remain high ( table 1 ), but 
this disadvantage must be weighed against the greatest 
and most durable obtainable biochemical control avail-
able and CSS; other apparently attractive salvage ap-
proaches, such as cryotherapy or high-intensity focused 
ultrasound are not free of (often serious) complications 
( table 4 ).
 Salvage brachytherapy (SBT) offers a realistic alterna-
tive to SRP ( table 4 ). Plotting of the BCR-free rates with 
the lengths of the follow-ups of the different SBT series 
revealed the same time-dependent tendency. The BCR-
FS decay was slightly faster than that observed for the sur-
gical series (α = 0.49 vs. –0.35) ( fig. 3 ).
 The superiority of SRP may be attributed not so much 
to a desirable positive effect of the associated LND on mi-
crometastases (as previously shown, the data are insuf-
ficient to defend this theory), but rather to the peculiar 
pattern of tumor recurrence after RT  [18] , i.e. in the peri-
urethral zone, which is generally spared during these ap-
proaches to minimize side effects  [100] .
 Conclusions 
 SRP seems to offer durable oncologic outcomes while 
potentially avoiding systemic noncurative therapy. How-
ever, rather high rates of incontinence and ED are associ-
ated with the procedure. The main issue continues to be 
the early detection of post-RT failure, which could facili-
tate further improvement in long-term oncologic results. 
This reinforces the need for proper patient counseling 
and selection. Robot-assisted prostatectomy has been 
largely described over the last years, with some potential 
advantages that are related to the three-dimensional mag-
nification vision and the more precise dissection. Promis-
ing new imaging tools could improve patient selection, 
thus avoiding the surgical morbidity associated with this 
type of challenging procedure.
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